Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 8%

Bulls say

10x Genomics Inc. is witnessing a significant uptick in Chromium reaction volumes, indicating a strong and resilient market presence despite anticipated pricing pressures. The company is projected to see substantial growth in consumables, potentially increasing 5-19 times per platform by 2027, highlighting a favorable trajectory for revenue generation beyond instrument sales. As the life sciences industry continues to evolve, the integrated solutions offered by 10x Genomics position the company for sustained success in analyzing complex biological systems.

Bears say

10x Genomics Inc. faces a challenging outlook due to a contraction in revenue in 2024, which is compounded by significant pricing pressure and flat to modestly lower sales volumes, with expectations for growth not resuming until 2027. The company's recent earnings report revealed larger-than-anticipated losses, as reflected in an EPS miss and a full-year revenue outlook that fell short of expectations. Furthermore, despite some segment expansion since the stock's peak in 2021, the growth has not matched forecasted levels from analysts, resulting in a decline of over 90% in stock value since that high point.

10X Genomics (TXG) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 13 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.